ISRCTN25173819已完成未知
Treatment of mature B-cell lymphoma/leukaemia
Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
- 2007 results in https://www.ncbi.nlm.nih.gov/pubmed/17132719 (added 25/01/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. B-large cell, small non-cleaved non-Hodgkin's disease or B-cell leukaemia
- •2. Stages I-IV
- •3. Aged over 6 months and under 18 years
- •4. No previous chemotherapy. Emergency radiotherapy or immunotherapy is permitted
- •5. No congenital immunodeficiency
- •6. No prior organ transplantation
- •7. No previous malignancy of any type
- •8. No medical contraindications to protocol treatments
- •9. Patients available for a minimal follow-up of 36 months
排除标准
- •Not provided at time of registration
研究者
相似试验
Unknown
2 期
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Mature B-Cell Leukemia Burkitt TypeBurkitt Lymphoma (BL)Unclassifiable Lymphoma Between DCBL and BLNCT05049473PETHEMA Foundation100
终止
3 期
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.Lymphoma, Large Cell, DiffuseNCT00322218Spectrum Pharmaceuticals, Inc68
已完成
1 期
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor CellsChronic Lymphocytic B-LeukemiaNCT00058786Baylor College of Medicine9
招募中
1 期
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaNon-Hodgkin LymphomaDiffuse Large B-Cell LymphomaBurkitt LymphomaLymphomaNCT03223610National Cancer Institute (NCI)155
进行中（未招募）
1 期
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaNon-Hodgkin LymphomaDiffuse Large B-Cell LymphomaBurkitt LymphomaLymphomaNCT04739813National Cancer Institute (NCI)34